Form 4: Akero Therapeutics COO Jonathan Young Sells Shares

Jonathan Young, Chief Operating Officer of Akero Therapeutics, sold shares of the company's common stock on March 4, 2025, according to a recent SEC filing.

Summary

• On March 4, 2025, Jonathan Young, the Chief Operating Officer of Akero Therapeutics, sold 11,447 shares of common stock at a weighted average price of $44.168.
• He also sold 38,553 shares at a weighted average price of $45.071.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
• Following these sales, Young directly owns 201,147 shares.
• He also has indirect ownership of 20,000 shares each through EA Irrevocable Trust, CM Irrevocable Trust, and JL Irrevocable Trust, for the benefit of his children.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a routine disclosure of stock sales under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

This filing is a routine disclosure of insider trading activity. It's important to monitor such filings to understand management's perspective on the company's valuation and future prospects. However, sales under 10b5-1 plans are less informative than discretionary trades.

Stakeholder Impact

• The stock sale by a key executive could create short-term uncertainty among shareholders.
• However, the existence of a pre-arranged trading plan mitigates concerns about insider information driving the sale.

Key Dates